ISARIC
  • Home
  • About
    • About
    • Hubs
    • Membership
    • People
  • Research
    • Research
    • Bubonic plague
    • COVID-19
    • Dengue
    • Ebola and other Filoviruses
    • H5Nx
    • Lassa fever
    • Nipah
    • Mpox
    • Severe Acute Hepatitis
  • Resources
    • Clinical Characterisation Protocol
    • Community Engagement
    • Core Outcome Sets
    • Current Opportunities
    • Data
    • Outputs
    • Resources
    • Stigma
  • Increasing Capacity
    • Increasing Capacity
    • CREDO
    • ISARIC Leadership Programme for Scientists
  • News & Events
    • News
    • Events
Select Page

Breakthrough treatments for Ebola virus disease, but no access—what went wrong, and how can we do better?

by Wajeeha Malik | May 16, 2024

From private incentives to public health need: rethinking research and development for pandemic preparedness

by Wajeeha Malik | May 16, 2024

An open-label, randomized, non-inferiority trial of the efficacy and safety of ciprofloxacin versus streptomycin + ciprofloxacin in the treatment of bubonic plague (IMASOY): study protocol for a randomized control trial

by Wajeeha Malik | May 14, 2024

Expanded Access Protocol for the use of tecovirimat for the treatment of monkeypox infection: a study protocol for an Expanded Access Programme

by Eamonn | May 9, 2024

Risk factors for post-COVID-19 condition (Long Covid) in children: a prospective cohort study

by Eamonn | May 3, 2024

Adults and children can develop post-Covid-19 condition (PCC) (also referred to as Long Covid). However, existing evidence is scarce, partly due to a lack of a standardised case definition, short follow up duration, and heterogenous study designs, resulting in wide...
« Older Entries
Next Entries »

Our Mission
Contact us
Opportunities
Funders
News

Follow ISARIC on X

Apply for membership
© ISARIC 2023 | Accessibility | Terms & Conditions | Site by Herd

Cookies Policy

Our Website uses cookies to improve your experience. Please visit our Cookies page for more information about cookies and how we use them.

Close